Philip Morris said it expects to record a loss on the sale of its inhaled-therapeutics unit to Molex Asia Holdings as it retools its pharmaceutical business.
Related Posts
Hyundai Motor India Makes Lackluster Debut After Record Listing
The South Korean automaker’s Indian affiliate a made a tepid trading debut after the biggest-ever listing in India.
ArcelorMittal Trims Steel Outlook After Earnings Slump
ArcelorMittal reported a 38% fall in second-quarter earnings on lower steel prices and shipments but said it expected demand to improve in the second half […]
Costco Earnings Rise in First Quarter Following Fee Increase
Executives at the warehouse-club chain said customers are starting to spend slightly more as inflation comes down, but many are gravitating toward higher and lower […]